ACXP vs. NOVN, BFRG, PPBT, NERV, KALA, YMTX, CKPT, ORGS, LUMO, and EFTR
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Novan (NOVN), Bullfrog AI (BFRG), Purple Biotech (PPBT), Minerva Neurosciences (NERV), Kala Pharmaceuticals (KALA), Yumanity Therapeutics (YMTX), Checkpoint Therapeutics (CKPT), Orgenesis (ORGS), Lumos Pharma (LUMO), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals vs.
Novan (NASDAQ:NOVN) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.
Novan has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -0.89, indicating that its stock price is 189% less volatile than the S&P 500.
Novan received 234 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Acurx Pharmaceuticals an outperform vote while only 61.92% of users gave Novan an outperform vote.
20.7% of Novan shares are owned by institutional investors. Comparatively, 13.1% of Acurx Pharmaceuticals shares are owned by institutional investors. 2.0% of Novan shares are owned by insiders. Comparatively, 30.9% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Novan. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals has a net margin of 0.00% compared to Novan's net margin of -128.61%. Acurx Pharmaceuticals' return on equity of -158.17% beat Novan's return on equity.
Novan presently has a consensus target price of $12.33, suggesting a potential upside of 972.46%. Acurx Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 381.10%. Given Novan's higher probable upside, equities research analysts plainly believe Novan is more favorable than Acurx Pharmaceuticals.
In the previous week, Novan had 8 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 9 mentions for Novan and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.49 beat Novan's score of -0.05 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Summary
Novan and Acurx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
